Cargando…

Ticagrelor – toward more efficient platelet inhibition and beyond

Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the therapy of atherothrombotic conditions due to their superiority over a standard combination of clopidogrel with acetylsalicylic acid in patients with acute coronary syndromes (ACS). A P2Y12 receptor antagonist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kubisa, Michał J, Jezewski, Mateusz P, Gasecka, Aleksandra, Siller-Matula, Jolanta M, Postuła, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775739/ https://www.ncbi.nlm.nih.gov/pubmed/29398917 http://dx.doi.org/10.2147/TCRM.S152369

Ejemplares similares

Bioresorbable Vascular Scaffolds—Dead End or Still a Rough Diamond?
por: Jeżewski, Mateusz P., et al.
Publicado: (2019)

MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review
por: Czajka, Pamela, et al.
Publicado: (2021)

Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel
por: Gasecka, Aleksandra, et al.
Publicado: (2020)

Expression Patterns of MiR-125a and MiR-223 and Their Association with Diabetes Mellitus and Survival in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome
por: Gager, Gloria M., et al.
Publicado: (2023)

Association Between the Expression of MicroRNA-125b and Survival in Patients With Acute Coronary Syndrome and Coronary Multivessel Disease
por: Gager, Gloria M., et al.
Publicado: (2022)

Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers
por: Traby, Ludwig, et al.
Publicado: (2019)

Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing
por: Ostrowska, Małgorzata, et al.
Publicado: (2019)

Plasma Trimethylamine-N-Oxide Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome
por: Eyileten, Ceren, et al.
Publicado: (2021)

P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets
por: Gasecka, Aleksandra, et al.
Publicado: (2020)

MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus
por: Pordzik, Justyna, et al.
Publicado: (2021)

Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study
por: Winter, Max-Paul, et al.
Publicado: (2019)

Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review
por: Pordzik, Justyna, et al.
Publicado: (2019)

Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
por: Marczewski, Margaret M, et al.
Publicado: (2010)

Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients
por: Prüller, Florian, et al.
Publicado: (2018)

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta‐Analysis
por: Gelbenegger, Georg, et al.
Publicado: (2021)

Pleiotropic Effects of Acetylsalicylic Acid after Coronary Artery Bypass Grafting—Beyond Platelet Inhibition
por: Siwik, Dominika, et al.
Publicado: (2021)

Ticagrelor and prasugrel are independent predictors of improved long‐term survival in ACS patients
por: Gager, Gloria M., et al.
Publicado: (2020)

MicroRNAs as Biomarkers of Systemic Changes in Response to Endurance Exercise—A Comprehensive Review
por: Soplinska, Aleksandra, et al.
Publicado: (2020)

Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial
por: Kubica, Jacek, et al.
Publicado: (2016)

Non-Vitamin K Oral Anticoagulants (NOAC) versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type
por: Eyileten, Ceren, et al.
Publicado: (2020)

Role of P2Y Receptors in Platelet Extracellular Vesicle Release
por: Gąsecka, Aleksandra, et al.
Publicado: (2020)

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
por: Gelbenegger, Georg, et al.
Publicado: (2019)

ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk Factors
por: Wicik, Zofia, et al.
Publicado: (2020)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

Alteration of circulating platelet-related and diabetes-related microRNAs in individuals with type 2 diabetes mellitus: a stepwise hypoglycaemic clamp study
por: Eyileten, Ceren, et al.
Publicado: (2022)

Infections as Novel Risk Factors of Atherosclerotic Cardiovascular Diseases: Pathophysiological Links and Therapeutic Implications
por: Szwed, Piotr, et al.
Publicado: (2021)

Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Reactivity in Patients With Minor Stroke or TIA
por: Yang, Yingying, et al.
Publicado: (2020)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

Interplay between Genetic and Clinical Variables Affecting Platelet Reactivity and Cardiac Adverse Events in Patients Undergoing Percutaneous Coronary Intervention
por: Siller-Matula, Jolanta M., et al.
Publicado: (2014)

Does ticagrelor effectively inhibit platelets in patients undergoing mild therapeutic hypothermia or it does not?
por: Kubica, Jacek
Publicado: (2022)

MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics
por: Jakubik, Daniel, et al.
Publicado: (2021)

Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2019)

Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension
por: Gąsecka, Aleksandra, et al.
Publicado: (2021)

Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
por: Johnson, Thomas W., et al.
Publicado: (2020)

Thrombosis-related circulating miR-16-5p is associated with disease severity in patients hospitalised for COVID-19
por: Eyileten, Ceren, et al.
Publicado: (2022)

When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y(12) Inhibition Induced by Ticagrelor
por: Capodanno, Davide, et al.
Publicado: (2020)

Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
por: Lomakin, Nikita, et al.
Publicado: (2019)

Temporal Variability of Platelet Reactivity in Patients Treated with Clopidogrel or Ticagrelor
por: Yun, Kyeong Ho, et al.
Publicado: (2019)

Comparison of ticagrelor and clopidogrel on platelet function and prognosis in unstable angina
por: Li, Chun, et al.
Publicado: (2022)

Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial
por: Baos, Sarah, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2jqca70bcemneqail6hhs2gm04